|
☐
|
QUARTERLY REPORT PERSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
|
|
|
|
☒
|
TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
|
|
|
|
|
For the transition period from
October 1, 2018
to
December 31,
|
|
Delaware
|
|
47-2847446
|
|
(State or other jurisdiction of
incorporation or organization)
|
|
(I.R.S. Employer
Identification No.)
|
|
HaCarmel 2
Yokneam, Israel 20692
|
|
06880
|
|
(Address of principal executive offices)
|
|
(Zip Code)
|
|
Class
|
|
Outstanding December 31, 2018
|
|
Common Stock, $0.0001 par value per share
|
|
16,198,578 shares
|
|
4
|
||
|
|
|
|
|
4
|
||
|
5
|
||
|
12
|
||
|
12
|
||
|
13
|
||
|
13
|
||
|
|
|
|
|
13
|
||
|
13
|
||
|
13
|
||
|
14
|
||
|
15
|
||
|
Page
|
|
|
F-2
|
|
|
F-3
|
|
|
F-4
|
|
|
F-5
|
|
|
F-6 F-15
|
|
Three months ended
December 31
|
||||||||||||
|
Note
|
2018
|
2017
|
||||||||||
|
Unaudited
|
Unaudited
|
|||||||||||
|
Operating expenses:
|
||||||||||||
|
Research and development
|
$
|
800
|
$
|
346
|
||||||||
|
Selling and marketing
|
269
|
124
|
||||||||||
|
General and administrative
|
386
|
303
|
||||||||||
|
Operating loss
|
1,455
|
773
|
||||||||||
|
Financial expenses (income), net
|
9
|
253
|
(54
|
)
|
||||||||
|
Net Loss
|
$
|
1,708
|
$
|
719
|
||||||||
|
Basic and diluted net loss per share
|
$
|
(0.11
|
)
|
$
|
(0.07
|
)
|
||||||
|
Weighted average number of ordinary shares used in computing basic and diluted loss per share
|
15,347,238
|
10,482,774
|
||||||||||
|
Ordinary shares
|
Additional Paid
in capital
|
Total
Shareholders'
Deficiency
|
||||||||||||||||||
|
Number
|
Amount
|
Accumulated
deficit
|
||||||||||||||||||
|
Balance as of September 30, 2017
|
10,358,219
|
$
|
1
|
$
|
1,297
|
$
|
(1,666
|
)
|
$
|
(368
|
)
|
|||||||||
|
Issuance of ordinary shares
|
213,859
|
*
|
237
|
-
|
237
|
|||||||||||||||
|
Issuance of shares with respect to the Reverse Merger
|
369,000
|
*
|
(349
|
)
|
-
|
(349
|
)
|
|||||||||||||
|
Conversion of convertible loan
|
1,500,000
|
*
|
1,244
|
-
|
1,244
|
|||||||||||||||
|
Share Based Compensation to non-employees
|
2,558,922
|
*
|
948
|
-
|
948
|
|||||||||||||||
|
Issuance of Warrants
|
-
|
-
|
42
|
-
|
42
|
|||||||||||||||
|
Net Loss
|
-
|
-
|
-
|
(5,148
|
)
|
(5,148
|
)
|
|||||||||||||
|
Balance as of September 30, 2018
|
15,000,000
|
$
|
1
|
$
|
3,419
|
$
|
(6,814
|
)
|
$
|
(3,394
|
)
|
|||||||||
|
Issuance of ordinary shares
|
821,740
|
1
|
316
|
317
|
||||||||||||||||
|
Conversion of convertible loans
|
349,338
|
*
|
307
|
-
|
307
|
|||||||||||||||
|
Share Based Compensation to non-employees
|
25,000
|
*
|
25
|
-
|
25
|
|||||||||||||||
|
Share Based Compensation to employees
|
2,500
|
*
|
12
|
-
|
12
|
|||||||||||||||
|
Issuance of Warrants
|
-
|
-
|
581
|
-
|
581
|
|||||||||||||||
|
Beneficial conversion feature related to convertible loan
|
-
|
-
|
750
|
-
|
750
|
|||||||||||||||
|
Net Loss
|
-
|
-
|
-
|
(1,708
|
)
|
(1,708
|
)
|
|||||||||||||
|
Balance as of December 31, 2018 (Unaudited)
|
16,198,578
|
$
|
2
|
$
|
5,410
|
$
|
(8,522
|
)
|
$
|
(3,110
|
)
|
|||||||||
|
Three months ended
December 31,
|
||||||||
|
2018
|
2017
|
|||||||
|
Cash flows from operating activities:
|
||||||||
|
Net Loss
|
$
|
(1,708
|
)
|
$
|
(719
|
)
|
||
|
Adjustments to reconcile loss to net cash used in operating activities:
|
||||||||
|
Depreciation and amortization
|
40
|
4
|
||||||
|
Financial expenses related to convertible loans
|
100
|
-
|
||||||
|
Financial expenses related to short-term loans
|
61
|
-
|
||||||
|
Loss from changes in fair value of warrants
|
89
|
-
|
||||||
|
Share based compensation expenses to non-employees
|
25
|
-
|
||||||
|
Share based compensation expenses to employees
|
12
|
-
|
||||||
|
Changes in assets and liabilities:
|
||||||||
|
Increase in other accounts receivable
|
(168
|
)
|
(1
|
)
|
||||
|
Increase in inventory
|
(35
|
)
|
-
|
|||||
|
Increase (Decrease) in advances from customers
|
(45
|
)
|
96
|
|||||
|
Increase (Decrease) in trade payables
|
(189
|
)
|
253
|
|||||
|
Increase (Decrease) in other accounts Payable
|
(53
|
)
|
196
|
|||||
|
Net cash used in operating activities
|
(1,871
|
)
|
(171
|
)
|
||||
|
Cash flows from investing activities
|
||||||||
|
Purchase of property and equipment
|
(100
|
)
|
(445
|
)
|
||||
|
Net cash used in investing activities
|
(100
|
)
|
(445
|
)
|
||||
|
Cash flows from financing activities:
|
||||||||
|
Issuance of ordinary shares
|
317
|
237
|
||||||
|
Proceeds from convertible loans
|
1,250
|
-
|
||||||
|
Proceeds from short-term loans
|
369
|
-
|
||||||
|
Issuance of Warrants
|
581
|
-
|
||||||
|
Repayment of short-term loan
|
(69
|
)
|
-
|
|||||
|
Net cash provided by financing activities
|
2,448
|
237
|
||||||
|
Increase (Decrease) in cash and cash equivalents and restricted cash
|
477
|
(379
|
)
|
|||||
|
Cash and cash equivalents at the beginning of the year
|
531
|
986
|
||||||
|
Cash and cash equivalents at the end of the year and restricted cash
|
$
|
1,008
|
$
|
607
|
||||
|
Supplemental disclosures of cash flow information:
|
||||||||
|
Cash and cash equivalents
|
$
|
921
|
$
|
360
|
||||
|
Restricted cash included in short and long term assets
|
87
|
247
|
||||||
|
$
|
1,008
|
$
|
607
|
|||||
|
Cash paid for interest
|
$
|
34
|
-
|
|||||
|
Supplemental disclosures of non- cash flow information:
|
||||||||
|
Conversion of convertible loans
|
$
|
307
|
$
|
1,244
|
||||
| NOTE 1:- |
GENERAL
|
| a. |
Seedo Corp. (the “Company”, “Our” or “We”), was incorporated on January 16, 2015, as GRCR Partners Inc. under the laws of Delaware. On September 17, 2018, the Company name was changed to Seedo Corp. We were solely a provider of risk management and asset protection (“RAP”) services for businesses, individuals and families. Post-Acquisition and Exchange with Eroll Grow Tech ("Eroll"), we have additionally acquired Eroll’s business as well ("acquisition Sunsidiary"). We produce the world’s first fully-automated plant growing device managed and controlled by an artificial intelligent algorithm, allowing consumers to grow their own herbs and vegetables effortlessly from seed to plant, while providing optimal conditions to assure premium quality produce year-round.
|
| NOTE 1:- |
GENERAL (Cont.)
|
| b. |
The Company operates in the field of development, and distribution of home growing automated machines for variety of herbs and vegetables worldwide.
|
| c. |
Basis of presentation:
|
| d. |
The Company has not generated revenues since inception. The Company has an accumulated deficit in the total amount of $8,522 as of December 31, 2018, the Company has negative operating cash flow in the total amount $1,871 for the period of three months ended December 31, 2018, further losses are anticipated in the development of its business. Those factors raise substantial doubt about the Company’s ability to continue as a going concern. The ability to continue as a going concern is dependent upon the Company obtaining the necessary financing to meet its obligations and repay its liabilities arising from normal business operations when they become due.
|
| NOTE 1:- |
GENERAL (Cont.)
|
| NOTE 2:- |
UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
|
| NOTE 3:- |
SIGNIFICANT ACCOUNTING POLICIES
|
| a. |
The significant accounting policies applied in the audited consolidated financial statements of the Company as disclosed in the Company's annual report on Form 10-K for the year ended September 30, 2018 filed with the SEC on January 15, 2019, are applied consistently in these unaudited interim condensed consolidated financial statements, except as discussed below.
|
| b. |
New Accounting Pronouncements
|
| NOTE 3:- |
SIGNIFICANT ACCOUNTING POLICIES (Cont.)
|
| c. |
Reclassification
|
| NOTE 4:- |
COMMITMENTS AND CONTINGENT LIABILITIES
|
|
2019
|
$
|
124
|
||
|
2020
|
124
|
|||
|
2021
|
124
|
|||
|
2022
|
41
|
|||
|
$
|
413
|
|
2019
|
$
|
104
|
||
|
2020
|
89
|
|||
|
2021
|
30
|
|||
|
$
|
223
|
|
2018
|
|
|
Dividend yield
|
0%
|
|
Risk-free interest rate
|
2.78%
|
|
Expected term (in years)
|
2
|
|
Volatility
|
126.23%
|
| a. |
As of December 31, 2018, and September 30, 2018 the Company recorded a provision in the amount of $520 and $496 respectively, that classified in other accounts payable, and during the three months ended December 31, 2018, and the year ended September 30, 2018, recorded expenses in the amount of $24 and $156 respectively, that classified in general and administrative expenses, to a related party for management services.
|
| b. |
On August 10, 2018, Eroll entered into a Convertible Loan Agreement (the “Agreement”) with Cannabics Pharmaceuticals Inc. ("Cannabics"), a US public company. Pursuant to the terms of the Agreement, Cannabics was obligated to invest up to $2,000 in Eroll Grow Tech. According to the agreement Cannabics Pharmaceuticals Inc. is obligated to invest $500 upon execution of the Agreement, to be followed by second $500 tranche within 90 days and third tranche in the amount of $1,000 (the "Second loan"), 90 days following that. On August 13, 2018, Cannabics Pharmaceuticals Inc. invested the initial $500 pursuant to its obligations under the Agreement.
|
| a. |
On August 2, 2018, Eroll received a loan in the amount of $100 with interest rate of 2% per month, the loan shall be paid on September 20, 2018. In case Eroll will merge into a traded company in the OTC the lender in eligible to receive 99,338 from the public company. As the exercise price of the nondetachable conversion feature was higher than the fair value of the share price at the commitment date, no BCF was recorded.
|
| b. |
During September 2018, Eroll received a loan from a private investor in the amount of $250 that bears 2% monthly interest rate which will be paid if Eroll will not merge into an OTC traded entity, Eroll has two options for the repayment of the loan, 1) Eroll repays the loan alongside with the interest in one payment after 30 days, 2) Eroll can convert the loan and the interest to shares of any future traded entity that Eroll plans to merge into in the amount of 250,000 shares in exchange for 1 per share.
|
|
2018
|
|
|
Dividend yield
|
0%
|
|
Risk-free interest rate
|
2.62%
|
|
Expected term (in years)
|
2
|
|
Volatility
|
134.48%
|
| c. |
On December 3, 2018 (the "Issuance Date"), the Company received a Convertible loan from third party (the "Lender"), the loan has 2 years term (the "Maturity Date"), in the amount of $550 which bears 10% annual interest rate (out of which $50 was directly transferred as finder fee).
|
| NOTE 8:- |
SHAREHOLDERS' DEFICIENCY
|
| a. |
As of December 31, 2018, and September 30, 2018, the Company's share capital is composed as follows:
|
|
December 31, 2018
|
September 30, 2018
|
|||||||||||||||
|
Authorized
|
Issued and outstanding
|
Authorized
|
Issued and outstanding
|
|||||||||||||
|
Number of shares
|
||||||||||||||||
|
Ordinary shares of $0.0001 par value each
|
500,000,000
|
16,198,578
|
500,000,000
|
15,000,000
|
||||||||||||
| NOTE 8:- |
SHAREHOLDERS' DEFICIENCY
(Cont.)
|
| b. |
Issuance of shares:
|
| 1. |
On October 23, 2018 the Company converted a loan in the amount of $250 to 250,000 ordinary shares with $0.0001 par value with a fair value of $208.(see note 7-b)
|
| 2. |
On October 23, 2018 the Company converted a loan in the amount of $100 to 99,338 ordinary shares with $0.0001 par value. (see note 7-a)
|
| 3. |
On December 10, 2018 the Company issued 51,570 ordinary shares with $0.0001 par value to a new investor, for a total amount of $67.
|
| 4. |
On December 11, 2018 the Company issued 2,500 ordinary shares with $0.0001 par value to 25 of its employees, each employee was entitled for 100 shares. As a result the Company recorded expenses in the amount of $12.
|
| 5. |
On December 23, 2018 the Company issued 25,000 ordinary shares with $0.0001 par value to one of its consultants, the fair value of the services received are $25.
|
| 6. |
On December 23, 2018 the Company issued 770,170 ordinary shares with $0.0001 par value to Cannabics as part of the Second Loan transfer with a relative fair value of $250.(see note 6-b)
|
|
Three months ended
December 31,
|
||||||||
|
2018
|
2017
|
|||||||
|
Bank commissions
|
$
|
21
|
$
|
7
|
||||
|
Financial expenses related to revaluation of Investment in warrants
|
89
|
-
|
||||||
|
Financial expenses related to loans
|
188
|
-
|
||||||
|
Foreign currency transactions and other
|
(45
|
)
|
(61
|
)
|
||||
|
$
|
253
|
$
|
54
|
|||||
| a. |
On January 15, 2019 the Company converted Cannabics Second Loan to 770,397 ordinary shares with a par value of $0.0001. (See note 6-b).
|
| b. |
On February 7, 2019 the Company received a conversion notice from a lender. The Company will convert the loan to 500,000 ordinary shares.
|
| c. |
On February 21, 2018, the Company executed a second Convertible Debenture, Securities Purchase Agreement (collectively, the “Agreements”) with
third party (the "Lender")
. Per the terms of the Agreements with
Lender
the Company was tendered $550, which is open with right of redemption for two years. Prior to the maturity date of the Convertible Debenture, the Company, at its option, has the right to redeem in cash in part or in whole, the amounts outstanding provided that as of the date of the redemption notice (i) the
volume-weighted average price
of the Company’s ordinary shares is less than $2 and (ii) there is no equity condition failures as defined therein. The Company shall pay an amount equal to the principal amount being redeemed plus a redemption premium equal to 20% of the outstanding amount being redeemed plus outstanding and accrued Interest.
|
| d. |
On March 11, 2019 the Company entered into a share purchase agreement with a new investor, Accordingly, the Company issued 70,000 ordinary shares with a par value of $0.0001, for a total consideration of $126. The Company also granted the investor a warrant to purchase 35,000 Ordinary Shares at a price of $3 per share for a period of 24 months.
|
| e. |
On March 11, 2019, the Company entered into a share purchase agreement with a new investor, according to the agreement the Company will issue 66,667 ordinary shares with a par value of $0.0001, for a total amount consideration of $100.
|
| f. |
On March 12, 2019 the Company entered into a share purchase agreement with a new investor, according to the agreement the Company issued 140,000 ordinary shares with a par value of $0.0001, for a total consideration of $252.
|
| g. |
On March 14, 2019, the Company executed an Agreement with Kibbutz Dan in northern Israel to establish the first industrial scale fully automated containerized farm for licensed pharmaceutical-grade medical cannabis, as disclosed in the 8K filing with the SEC of March 19, 2019.
|
| · |
Sections 14A(a) and (b) of the Exchange Act, which require companies to hold stockholder advisory votes on executive compensation and golden parachute compensation;
|
| · |
The requirement to provide, in any registration statement, periodic report or other report to be filed with the Securities and Exchange Commission (the “Commission” or “SEC”), certain modified executive compensation disclosure under Item 402 of Regulation S-K or selected financial data under Item 301 of Regulation S-K for any period before the earliest audited period presented in our initial registration statement;
|
| · |
Compliance with new or revised accounting standards until those standards are applicable to private companies;
|
| · |
The requirement under Section 404(b) of the Sarbanes-Oxley Act of 2002 to provide auditor attestation of our internal controls and procedures; and
|
| · |
Any Public Company Accounting Oversight Board (“PCAOB”) rules regarding mandatory audit firm rotation or an expanded auditor report, and any other PCAOB rules subsequently adopted unless the Commission determines the new rules are necessary for protecting the public.
|
| • |
85,000 followers on Facebook
|
| • |
40,000 followers on Instagram
|
| • |
250,000 subscribers
|
| • |
More than 50 million views on Facebook
|
| • |
1 million views on YouTube
|
| • |
Automated home growing device
|
| • |
Simplifying the seed to harvest process with seamless technology
|
| • |
Growth cycle operated and monitored by mobile app
|
| • |
Self-regulating climate control system
|
| • |
No prior knowledge needed
|
| • |
Simple installment – water, electricity and Wi-Fi
|
| • |
100% pesticide free
|
| · |
Deliver pre orders of the home cultivator
|
| · |
Increase sales and marketing efforts.
|
| · |
Start and increase home cultivator manufacturing quantities.
|
| · |
Progress the commercial container product R&D efforts
|
| · |
Continue with the corporate governance, risk management, compliance and regulatory reporting activities of the Company while considering our targets and objectives in this regard.
|
| · |
Strengthen our Board of Directors by adding world class key members which will better enable the Company to be recognized as a world-wide leader in its field.
|
|
Dated: March 20, 2019
|
By:
|
/s/ Zohar Levy
|
|
|
|
|
Zohar Levy
Director, Chief Executive Officer
|
|
|
SEEDO CORP.
|
|
Signature
|
Title
|
Date
|
|
Zohar Levy
|
Zohar Levy
Director, Chief Executive Officer
|
March 20, 2019
|
|
1.
|
I have reviewed Seedo Corp. Company’s Quarterly report on Form 10-QT for the three months ended December 31, 2018;
|
|
2.
|
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
|
|
3.
|
Based on my knowledge, the unaudited condensed financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the small business issuer as of, and for, the periods presented in this report;
|
|
4.
|
The small business issuer’s other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the small business issuer and have:
a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the small business issuer, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b) Evaluated the effectiveness of the small business issuer’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures as of the end of the period covered by this report based on such evaluation; and
c) Disclosed in this report any change in the small business issuer’s internal control over financial reporting that occurred during the small business issuer’s fourth fiscal quarter that has materially affected, or is reasonably likely to materially affect, the small business issuer’s internal control over financial reporting; and
d) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of the unaudited condensed financial statements for external purposes in accordance with generally accepted accounting principles;
|
|
5.
|
The small business issuer’s other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the small business issuer’s auditors and the audit committee of the small business issuer’s board of directors (or persons performing the equivalent functions):
a) All significant deficiencies and material weaknesses in the design or operation of internal controls over financial reporting which are reasonably likely to adversely affect the small business issuer’s ability to record, process, summarize and report financial information; and
b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the small business issuer’s internal control over financial reporting.
|
|
Date: March 20, 2019
|
By:
|
/s/ Zohar Levy
|
|
|
|
Zohar Levy
Director, Chief Executive Officer
|
||
|
|
Seedo Corp.
|
||
|
1.
|
I have reviewed Seedo Corp. Company’s Quarterly report on Form 10-QT for the three months ended December 31, 2018;
|
|
2.
|
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
|
|
3.
|
Based on my knowledge, the unaudited condensed financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the small business issuer as of, and for, the periods presented in this report;
|
|
4.
|
The small business issuer’s other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the small business issuer and have:
a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the small business issuer, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b) Evaluated the effectiveness of the small business issuer’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures as of the end of the period covered by this report based on such evaluation; and
c) Disclosed in this report any change in the small business issuer’s internal control over financial reporting that occurred during the small business issuer’s fourth fiscal quarter that has materially affected, or is reasonably likely to materially affect, the small business issuer’s internal control over financial reporting; and
d) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
|
|
5.
|
The small business issuer’s other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the small business issuer’s auditors and the audit committee of the small business issuer’s board of directors (or persons performing the equivalent functions):
a) All significant deficiencies and material weaknesses in the design or operation of internal controls over financial reporting which are reasonably likely to adversely affect the small business issuer’s ability to record, process, summarize and report financial information; and
b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the small business issuer’s internal control over financial reporting.
|
|
Date: March 20, 2019
|
By:
|
/s/ Uri Birenberg
|
|
|
|
Uri Birenberg
Chief Financial Officer
|
||
|
|
Seedo Corp.
|
||
|
1.
|
The report of the Company for the three months period ended December 31, 2018 as filed with the Securities and Exchange Commission on this date (the “Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
|
|
2.
|
The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.
|
|
Date: March 20, 2019
|
By:
|
/s/ Zohar Levy
|
|
|
Zohar Levy
Chief Executive Officer
|
|
|
|
SEEDO CORP.
|
|
|
1.
|
The report of the Company for the three months period ended December 31, 2018 as filed with the Securities and Exchange Commission on this date (the “Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
|
|
2.
|
The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.
|
|
Date: March 20, 2019
|
By:
|
/s/ Uri Birenberg
|
|
|
Uri Birenberg
Chief Financial Officer
|
|
|
|
SEEDO CORP.
|
|